股票代码：002750 股票简称：*ST 龙津 公告编号：2024-046 昆明龙津药业股份有限公司 股票交易严重异常波动公告 公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 昆明龙津药业股份有限公司（以下简称"公司"）股票（证券代码：002750， 证券简称：*ST 龙津）连续三个交易日内（2024 年 5 月 16 日、2024 年 5 月 17 日、2024 年 5 月 20 日）收盘价格涨跌幅偏离值累计达到-12%，根据《深圳证券 交易所交易规则》的规定，属于股票交易异常波动的情形。 公司董事会确认，公司目前没有其他根据深圳证券交易所《股票上市规则》 等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协 议等；董事会也未获悉公司有根据《股票上市规则》等有关规定应予以披露而未 披露的、对公司股票交易价格产生较大影响的信息；公司前期披露的信息不存在 需要更正、补充之处。 四、风险提示 根据《股票上市规则》第 9.3.1 条第一款第（一）项的规定，公司股票交易 自 2024 年 5 月 6 日被深圳证券交易所实 ...

股票代码：002750 股票简称：*ST 龙津 公告编号：2024-045 昆明龙津药业股份有限公司 股票交易异常波动公告 公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 昆明龙津药业股份有限公司（以下简称"公司"）股票（证券代码：002750， 证券简称：*ST 龙津）连续 3 个交易日内（2024 年 5 月 13 日、2024 年 5 月 14 日、2024 年 5 月 15 日）收盘价格涨跌幅偏离值累计达到-12%，根据《深圳证券 交易所交易规则》的规定，属于股票交易异常波动的情形。 二、关注、核实情况说明 针对本次股票交易异常波动的情形，公司对有关事项进行核查，并书面函询 了公司控股股东及实际控制人，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处；近期公共传媒没有报 道可能或已经对本公司股票交易价格产生较大影响的未公开重大信息；近期公司 经营情况及内外部经营环境未发生重大变化，预计未发生重大变化；公司不存在 关于公司的应披露而未披露的重大事项。 2、控股股东和实际控制人不存在关于本公司的应披露而未 ...

深 圳 证 券 交 易 所 关于对昆明龙津药业股份有限公司 2023 年年报的问询函 公司部年报问询函〔2024〕第 121 号 昆明龙津药业股份有限公司董事会： 我部在对你公司 2023 年年度报告（以下简称"年报"）进行 审查的过程中，关注到如下事项： 1.2023 年度，你公司实现营业收入 8,662.25 万元，同比下 降 29.56%；2019 年至 2023 年，归属于上市公司股东的扣除非经 常性损益的净利润（以下简称"扣非后净利润"）分别为-3,988.60 万元、-252.59 万元、-1,030.45 万元、-5,734.40 万元、-8,110.48 万元，连续五年为负。 （1）请你公司结合行业发展情况、公司主营业务发展情况、 主要产品或服务的核心竞争力、毛利率变化情况以及资产结构及 债务情况等，说明你公司连续亏损的主要原因，为提高主业盈利 能力及改善持续经营能力已采取或拟采取的具体措施，你公司持 续经营能力是否存在重大不确定性，是否触及本所《股票上市规 1 请年审会计师对问题（1）（2）核查并发表明确意见。 2.年报显示，报告期内公司营业收入扣除项目合计 765.95 万元，其中未形成稳 ...

股票代码：002750 股票简称：*ST 龙津 公告编号：2024-044 昆明龙津药业股份有限公司 股票交易异常波动公告 公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 昆明龙津药业股份有限公司（以下简称"公司"）股票（证券代码：002750， 证券简称：*ST 龙津）连续 3 个交易日内（2024 年 5 月 8 日、2024 年 5 月 9 日、 2024 年 5 月 10 日）收盘价格涨跌幅偏离值累计达到-12%，根据《深圳证券交易 所交易规则》的规定，属于股票交易异常波动的情形。 二、关注、核实情况说明 针对本次股票交易异常波动的情形，公司对有关事项进行核查，并书面函询 了公司控股股东及实际控制人，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处；近期公共传媒没有报 道可能或已经对本公司股票交易价格产生较大影响的未公开重大信息；近期公司 经营情况及内外部经营环境未发生重大变化，预计未发生重大变化；公司不存在 关于公司的应披露而未披露的重大事项。 2、控股股东和实际控制人不存在关于本公司的应披露而未披 ...

昆明龙津药业股份有限公司（以下简称"公司"）股票（证券代码：002750， 证券简称：*ST 龙津）连续 2 个交易日内（2024 年 5 月 6 日、2024 年 5 月 7 日） 收盘价格涨跌幅偏离值累计达到-12%，根据《深圳证券交易所交易规则》的规 定，属于股票交易异常波动的情形。 二、关注、核实情况说明 针对本次股票交易异常波动的情形，公司对有关事项进行核查，并书面函询 了公司控股股东及实际控制人，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处；近期公共传媒没有报 道可能或已经对本公司股票交易价格产生较大影响的未公开重大信息；近期公司 经营情况及内外部经营环境未发生重大变化，预计未发生重大变化；公司不存在 关于公司的应披露而未披露的重大事项。 2、控股股东和实际控制人不存在关于本公司的应披露而未披露的重大事项， 或处于筹划阶段的重大事项；股票异常波动期间控股股东、实际控制人未买卖公 司股票。 股票代码：002750 股票简称：*ST 龙津 公告编号：2024-042 昆明龙津药业股份有限公司 股票交易异常波动公告 公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 ...

股票代码：002750 股票简称：*ST 龙津 公告编号：2024-041 昆明龙津药业股份有限公司 董事会审计委员会对会计师事务所 2023 年度 履职情况评估总结报告 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 治理准则》、《国有企业、上市公司选聘会计师事务所管理办法》、《深圳证券 交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等规定和要求， 董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将昆明龙津药 业股份有限公司（以下简称"公司"）董事会审计委员会对会计师事务所 2023 年 度履行监督职责的情况评估总结如下： 一、年审会计师事务所基本情况 （一）会计师事务所基本情况 中审众环会计师事务所（特殊普通合伙）（以下简称"中审众环"或"审计 机构"）始创于 1987 年，是全国首批取得国家批准具有从事证券、期货相关业 务资格及金融业务审计资格的大型会计师事务所之一。根据财政部、证监会发布 的从事证券服务业务会计师事务所备案名单，中审众环具备股份有限公司发行股 份、债券审计机构的资格。2013 年 11 月，按照国家财政部等有关要求转制为特 殊普通合伙制。注册 ...

Financial Performance - The company's operating revenue for 2023 was ¥86,622,523.39, a decrease of 29.56% compared to ¥122,965,512.11 in 2022[20]. - The net profit attributable to shareholders for 2023 was -¥70,941,451.11, representing a decline of 26.42% from -¥56,116,510.96 in 2022[20]. - The cash flow from operating activities for 2023 was -¥39,260,741.79, a significant decrease of 171.83% compared to -¥14,443,094.88 in 2022[20]. - The basic and diluted earnings per share for 2023 were both -¥0.1771, down 26.41% from -¥0.1401 in 2022[20]. - Total assets at the end of 2023 were ¥631,634,251.67, a decrease of 15.47% from ¥747,205,227.88 at the end of 2022[20]. - The total operating revenue for 2023 was ¥86,622,523.39, a decrease of 29.56% compared to ¥122,965,512.11 in 2022[54]. - The pharmaceutical manufacturing sector generated ¥74,492,475.31, accounting for 86.00% of total revenue, with a year-on-year decline of 35.57%[54]. - The company's gross profit margin for the pharmaceutical manufacturing sector was 63.19%, down 19.36% from the previous year[55]. - The sales volume of the pharmaceutical manufacturing sector decreased by 30.62% to 539.66 million bottles, while production volume dropped by 92.33% to 110.13 million bottles[57]. Business Strategy and Operations - The company has established a full industry chain layout for its core products, including the injection of Ligusticum Chuanxiong and injection of Fibrinolytic Enzyme, which have continuously entered the national medical insurance catalog[42]. - The company has invested in subsidiaries focused on innovative drug research and development, high-end chemical generic drugs, industrial hemp cultivation, and health and daily chemical products[39]. - The company has optimized its sales channels and strengthened promotion efforts in provinces with previously weak coverage to improve market penetration[90]. - The company has established a comprehensive marketing system, covering all 31 provinces in China, to support product access and sales, adapting strategies to mitigate risks from centralized procurement policies[49]. - The company is actively seeking suitable investment targets in the pharmaceutical and health sectors to achieve rapid and healthy development through R&D, cooperation, and mergers and acquisitions[91]. Research and Development - The company has invested 20% of its sales revenue in R&D, with over 20% of its workforce dedicated to research, supporting strategic upgrades and sustainable development[45]. - The company has achieved production approval for several cardiovascular generic drugs, enhancing its competitive position in the market[65]. - The company has invested in nearly 20 related raw material and formulation patents for its core product, Ligusticum Chuanxiong, and continues to allocate resources for post-marketing clinical research and secondary development[42]. - The company is investing heavily in R&D, allocating 100 million yuan for the development of new technologies in the biopharmaceutical sector[115]. - The company is investing heavily in R&D, with a budget increase of 15% to enhance product innovation[161]. Market Challenges - The company has faced challenges due to ongoing healthcare reforms and cost control measures in the pharmaceutical industry, impacting its operational performance[31]. - The company is facing significant revenue pressure due to the ongoing price reductions from centralized procurement affecting its core product, the injection of Ligusticum chuanxiong[90]. - The company's core product, the injection of Ligusticum Chuanxiong, experienced a price drop of 67% due to centralized procurement, leading to a continued downward trend in performance[43]. - The company faces risks related to the decline in unit price and sales volume of its core products amid uncertainties in contract orders and actual usage in medical institutions[200]. Corporate Governance and Compliance - The financial report is guaranteed to be true, accurate, and complete by the company's management team, including the responsible person and accounting head[3]. - The company maintains a strict compliance with information disclosure regulations, ensuring timely, fair, and accurate information for investors[107]. - The company has established a complete and independent business structure, ensuring no reliance on the controlling shareholder for operations[108]. - The company has a fully independent financial institution, with its own accounting system and decision-making processes, free from interference by the controlling shareholder[109]. - The company has not faced any regulatory penalties in the past three years, ensuring compliance with securities regulations[125]. Environmental and Social Responsibility - The company has a commitment to environmental and social responsibility, as outlined in its annual report[5]. - Longjin Pharmaceutical actively participates in social responsibility initiatives, including educational funding and community support projects[154]. - The company supports rural revitalization by improving the income of local farmers through contracts and technical guidance in its industrial hemp business[155]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion yuan[115]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan earmarked for potential targets[115]. - The company has provided a future outlook with a revenue guidance of 1.5 billion yuan for the next fiscal year, indicating a growth target of 25%[125]. - The company plans to invest more resources in the health sector, leveraging its technology advantages in plant-based and peptide drugs[53]. Shareholder Relations - The company reported a plan not to distribute cash dividends, issue bonus shares, or increase capital from reserves[6]. - The board has approved a dividend payout of 0.5 yuan per share, reflecting a commitment to returning value to shareholders[115]. - The company has committed to maintaining a dividend payout ratio of 30% of net profits, ensuring shareholder returns[161].

Financial Performance - The company's revenue for Q1 2024 was ¥26,388,422.34, representing a 22.43% increase compared to ¥21,553,840.94 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥4,491,776.72, an improvement of 44.66% from a loss of ¥8,117,275.16 in the previous year[4] - The net loss attributable to the parent company was reduced by 61.74% to ¥3,105,602.00 from ¥8,117,275.16 in the same period last year[9] - Net loss for Q1 2024 was CNY 5,566,204.56, an improvement from a net loss of CNY 9,414,778.99 in Q1 2023, indicating a reduction in losses by approximately 40.5%[21] - The company reported a basic and diluted earnings per share of -0.0112 for Q1 2024, an improvement from -0.0203 in Q1 2023[22] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥4,764,302.80, a reduction of 87.59% compared to a net outflow of ¥38,395,753.41 last year[4] - The company's cash and cash equivalents decreased by 38.48% to ¥129,653,449.82 from ¥210,737,426.26 due to changes in cash management products[9] - The company's cash flow from operating activities showed a significant improvement, with a reduction in cash outflow compared to the previous quarter[22] - The total cash outflow from operating activities was 30,035,289.88 CNY, down from 66,951,138.63 CNY, showing a reduction in cash outflows[23] - The ending balance of cash and cash equivalents decreased to 129,653,249.19 CNY from 143,554,364.11 CNY, a decline of 9.6%[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥641,276,844.03, reflecting a 1.53% increase from ¥631,634,251.67 at the end of the previous year[4] - The total current assets increased from CNY 384.06 million to CNY 393.64 million, an increase of about 2%[16] - Total liabilities rose to CNY 105,716,563.79 in Q1 2024, up from CNY 90,507,766.87 in Q1 2023, representing an increase of 16.8%[18] - The total equity attributable to shareholders decreased to CNY 507,395,172.08 in Q1 2024 from CNY 511,886,948.80 in Q1 2023, a decline of 0.9%[18] Operational Metrics - Accounts receivable increased by 55.98% to ¥18,915,136.60, driven by revenue growth in the current period[9] - The inventory decreased from CNY 28.65 million to CNY 26.43 million, a reduction of about 7.7%[16] - Total operating costs for Q1 2024 were CNY 33,756,765.30, up from CNY 32,031,811.64 in the same period last year, reflecting a year-over-year increase of 5.4%[20] - The cash inflow from sales of goods and services was 21,710,973.97 CNY, down from 26,559,717.08 CNY, representing a decrease of 18.4%[23] - Payments to employees increased to 10,302,516.84 CNY from 9,319,478.29 CNY, reflecting an increase of 10.6% in labor costs[23] Research and Development - Research and development expenses decreased by 51.58% to ¥1,992,368.82, reflecting a reduction based on project progress[9] - Research and development expenses for Q1 2024 were CNY 1,992,368.82, down from CNY 4,114,891.99 in Q1 2023, indicating a decrease of 51.6%[20] Financing Activities - The company obtained short-term bank loans, resulting in a net cash inflow from financing activities of ¥9,980,000.00[9] - Cash inflow from financing activities was 9,980,000.00 CNY, with no inflows recorded in the previous period, indicating new financing efforts[25] Market and Product Insights - The core product, the injection of light orchid flower extract, has seen a price drop of 67% compared to pre-bid procurement prices due to centralized procurement policies[12] - The company is currently facing risks related to the decline in sales volume and pricing of its core products due to centralized procurement execution[12] - The company has received a total of CNY 4 million in performance compensation from the original shareholders of its subsidiary, which will positively impact the 2024 profit[14] - The company has actively communicated with the original shareholders of its subsidiary to ensure compliance with performance commitments[14] - The company plans to focus on market expansion and new product development in the upcoming quarters to enhance revenue growth[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 56,743[11] - The company holds 39.40% of its shares through Kunming Qunxing Investment Co., Ltd., which is the largest shareholder[11] Audit Status - The company has not undergone an audit for the first quarter report, indicating that the financial results are unaudited[26]

股票代码：002750 股票简称：龙津药业 公告编号：2024-023 公司 2023 年年度报告披露后，若最近一个会计年度经审计的净利润为负值 且营业收入低于 1 亿元，或者追溯重述后最近一个会计年度净利润为负值且营业 收入低于 1 亿元（上述净利润以扣除非经常性损益前后孰低者为准；营业收入应 当扣除与主营业务无关的业务收入和不具备商业实质的收入），根据《深圳证券 交易所股票上市规则》第 9.3.1 条规定，公司股票交易可能被实施退市风险警示 （股票简称前冠以"*ST"字样）。 二、其他事项 1、为充分提示以上风险，根据《深圳证券交易所股票上市规则》9.3.2 条规 定，公司已于 2024 年 1 月 29 日披露《关于公司股票交易可能被实施退市风险警 示的提示性公告》（公告编号：2024-015），于 2024 年 2 月 29 日披露《关于公 司股票交易可能被实施退市风险警示的提示性公告》（公告编号：2024-017）。 2、截止本公告披露日，公司 2023 年年度报告审计工作仍在进行中，最终财 务数据以公司正式披露的经审计后的 2023 年年度报告为准。 3、公司所有公开披露的信息均以在指定信息披露媒 ...

股票代码：002750 股票简称：龙津药业 公告编号：2024-022 昆明龙津药业股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、进行现金管理的审批情况 2、公司内部风险控制 （1）经公司股东大会授权公司董事会及管理层负责办理相关事宜，公司将严 格遵守审慎投资原则，选择银行、证券公司等持牌金融机构的中、低风险投资品种。 昆明龙津药业股份有限公司（以下简称"公司"）于 2023 年 12 月 12 日召开 第五届董事会第十九次会议、2024 年 1 月 3 日召开 2024 年第一次临时股东大会， 审议通过了《关于使用闲置自有资金进行现金管理的议案》，同意公司及纳入公司 合并报表范围的子公司使用余额不超过人民币三亿五仟万元（35,000 万元）的自有 闲置资金进行现金管理，投资的品种包括结构性存款、理财产品、收益凭证、集合 资管（信托）计划、货币基金、国债、国债逆回购等中低风险且流动性好的产品， 公司股东大会授权董事会及管理层负责办理具体实施相关事宜，授权期限为股东大 会审议通过之日起至一年内。 上 ...